Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) will have its CEO, Nancy Simonian, M.D., present at the 39th Annual J.P. Morgan Healthcare Conference on January 7 at 2:50 p.m. ET. The presentation will be accessible via a live webcast on the Syros website, with an archived replay available for 30 days post-event. Syros is focused on developing medicines to control gene expression and has a clinical-stage pipeline, including innovative treatments for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors. For more details, visit www.syros.com.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39^th Annual J.P. Morgan Healthcare Conference. Details are as follows:

39^th Annual J.P. Morgan Healthcare Conference:
Date: Thursday, January 7
Time: 2:50 p.m. ET

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005054/en/

FAQ

When is Syros Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Syros Pharmaceuticals is presenting on January 7 at 2:50 p.m. ET.

How can I watch the Syros Pharmaceuticals presentation?

The presentation will be available via live webcast on the Syros website.

What is Syros Pharmaceuticals working on?

Syros is developing medicines that control gene expression, focusing on oncology and monogenic diseases.

What are the key drugs in Syros Pharmaceuticals' pipeline?

Key drugs include SY-1425, SY-2101, and SY-5609, targeting various blood cancers and solid tumors.

Is there a replay of the Syros Pharmaceuticals presentation available?

Yes, an archived replay will be available for approximately 30 days after the presentation.